RePORT International Highlights

The Colloquium Health in Motion: Infectious Diseases on the Move will bring together researchers, public health professionals, policy makers and innovators from around the world. Together, we will explore how movement of people, pathogens, vectors, environments and policies is reshaping the dynamics of infectious diseases, the resilience of health systems, and the strategies needed to respond to them. Date 15–17 November, 2026. The Colloquium will be hosted in Addis Ababa, Ethiopia

The 5th International Conference on Public Health in Africa (CPHIA 2026) will be held from 1–5 November 2026 in Addis Ababa, Ethiopia. Co-hosted by the Africa Centres for Disease Control and Prevention (Africa CDC) and the Government of Ethiopia, this conference will bring together political leaders, policymakers, researchers, innovators, civil society, and youth. Participants will work to define Africa’s pathway to stronger, more resilient health systems and to reducing dependence on foreign aid.

The 2027 ASM Microbe meeting will continue the newly re-envisioned tri-located structure launched in 2026, bringing together 3 specialized meetings under the ASM Microbe umbrella: ASM Health Meeting, ASM Applied and Environmental Microbiology Meeting, ASM Mechanism Discovery Meeting. Together, these meetings provide comprehensive access to the latest advances across the microbial sciences while fostering meaningful cross-disciplinary collaboration. It will be held June 22-25, 2027 in Chicago

Donations are a contribution, grant, or payment in cash or in kind, made by Amgen to a not-for-profit and/or tax exempt organization without expectation of something in return other than customary donor recognition of incidental value. Amgen may make only donations to Qualified Recipients as set forth in the Eligibility Criteria section, to further an educational, scientific or other charitable purpose. As part of Amgen's mission to serve patients, Amgen makes donations to qualified members of the U.S. healthcare community for the following purposes: The support of science, technology, medicine, healthcare or education; or Education of the public on disease states, medical conditions, science or technology; or In furtherance of other genuine philanthropic and charitable purposes that are consistent with Amgen's scientific and disease-state interests.

Advancing Military and Civilian Medical Research Including Military Infectious Diseases Research Program Closing Date: Sep 30, 2027

The ERC plans to launch the grant competitions under its 2027 Work Programme between July 2026 and June 2027, with the calls for proposals introducing several changes to the eligibility rules for applications. Please refer to the website for the details.

DEADLINE FOR SUBMISSION: 31 October 2026 There are up to two awards made each year available: one for clinical research and the other one for basic research. These awards will be made to outstanding young investigators in the field of paediatric infectious diseases. he winner will receive: Euro 5,000 to be paid to the host institution for research purposes only. The host institution is not allowed to take any overhead on this amount (see declaration below) At the time of being offered the award successful candidates will be invited to attend that year's ESPID Annual Meeting with registration, travel and accommodation being offered (if already registered, this will be refunded). Please be aware the travel and accommodation are subject to ESPID Rules and maximum amounts apply The Young Investigator’s medal The winner will be asked to give a 5 minute presentation of their work at the ESPID Annual Meeting

MULTIPLE DEADLINES Please refer to the website for the details Global Health EDCTP3 invests in global health through funding collaborative research and innovation projects tackling infectious diseases and supporting activities for research capacity building in Africa. Check the website for detailed information on the calls for proposals.

Early Registration Deadline: 30 July 2026 Congress Dates: 10-13 November 2026 The Early Career Researcher Grants are available to support eligible applicants attending the 21st ICID Congress. These grants aim to reduce financial barriers and encourage participation from early-career professionals. This support opportunity is a part of the abstract submission process. You cannot apply for this Grant without submitting an abstract. The Grant Consists Of: Free registration: Complimentary access to Scientific sessions only. Workshops are not included. Hotel accommodation: 4 nights in a single room at a specified hotel, booked and paid for directly by the Congress organizers. Travel reimbursement: Economy class travel only. Reimbursement up to a predetermined amount based on the country of origin of the grant recipient, subject to receipt submission.

ISID mission is to empower clinical health experts and allied professionals to prevent, investigate, and manage infectious diseases within a One Health context. The ISID is committed to equity, prioritizing support for countries and regions with limited resources and disproportionately high infectious disease burdens. The conference will be in Madrid November 10-13, 2026

Abstract Submission Deadline: August 21st, 2026 We are pleased to announce that the 16th edition of the International Workshop on Clinical Pharmacology of Tuberculosis Drugs will take place October 14-15, 2026, as a virtual meeting. This abstract-driven workshop has been a leading annual meeting in the field of tuberculosis (TB) pharmacology since 2008. The aim of the meeting is to contribute to the optimization of TB treatment by providing an independent platform for the presentation and discussion of the latest scientific developments in TB pharmacology. If you work in TB, you are invited to join us. This includes preclinical and clinical pharmacology researchers from academia and industry; medical doctors, pharmacists, and pharmacologists involved in clinical management of TB patients; laboratorians, nurses, and PhD students; and representatives from regulatory or non-governmental organizations active in the TB field. The program consists of oral presentations that will be put in perspective, with a translation to clinical care where possible, by selected experts at the end of each workshop session. In addition, there will be e-poster abstract presentations. The workshop is informal in setting and is meant to be interactive.

The 2027 Keystone Conference on TB will be held Mar 1-4, 2027 at Mercure London Earls Court, London, United Kingdom. mportant Deadlines Early Registration Deadline: December 29, 2026 Scholarship Deadline: November 3, 2026 Global Health Award Deadline: September 29, 2026 Short Talk Abstract Deadline: November 3, 2026 Poster Abstract Deadline: February 8, 2027 Clinical detection and treatment of tuberculosis are still cumbersome, and new effective vaccines are not yet available. However, basic science is contributing significant new insights that can improve patient care and may ultimately control the pandemic. This symposium will foster interactions between basic and clinician scientists to focus research on the most prominent clinical needs and reciprocally to translate key findings into novel preventive, care and control strategies. Discussions will specifically focus on the heterogeneity of the host-pathogen interactions that underlie disease and represent a fundamental challenge to achieving this vision. By considering the full spectrum of disease, diversity of the host and pathogen, and environmental factors influencing immune control, we will refocus interventional strategies on those that will be most effective in the real world. Ultimately these insights should lead to the rational design and testing of vaccines that can prevent infection and disease in the global population, preventing not only acute disease but also post-TB sequelae.

Grants Deadline AT MIDNIGHT CST Spring: February 1 - March 31 Fall: August 1 - September 30 The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation is seeking highly innovative and groundbreaking medical research proposals in both basic biological and applied research that will have the greatest impact on scientific knowledge and human health. The Foundation focuses on basic science and some translational - not clinical - research. All applications must be approved by the University Provost or the Vice President of Research, and should be submitted through the office of sponsored research or like office that provides institutional approval for the request. Studies selected through an internal competition are preferred. Applications submitted by an individual researcher will NOT be considered.

Grant schedules and submission deadlines are fixed annually. (Spring and Fall cycles) The Mathers Foundation supports basic research with translational potential in areas such as immunology, microbiome, structural biology, cancer, genetics, stem cells, and neuroscience. We fund work that can lead to major advances in scientific understanding and human health. Please refer to the website for the details.

DEADLINE FOR APPLICATION: 1 November 2026 The Department of Laboratory Medicine at Memorial Sloan Kettering Cancer Center offers a two-year Clinical Microbiology Fellowship. This fellowship offers training for doctoral-level scientists interested in acquiring knowledge and skills necessary to direct a clinical microbiology laboratory. The fellowship will provide both general training in clinical microbiology as well as specialized training for diagnostic microbiology in immunocompromised patients. The fellow will obtain training in all subspecialties of clinical microbiology and develop knowledge of both conventional and molecular diagnostic methods for identification and antimicrobial susceptibility testing of bacteria, mycobacteria, fungi, and rapid detection of viruses and parasites. Additionally, the fellow will develop skills in laboratory management, clinical consultation related to microbiology and infectious diseases and interpretation, and clinical correlation of laboratory data. A strong emphasis is also placed on laboratory research, diagnostic assays development, and outcome studies in immunocompromised patients.

The Jimmy and Rosalynn Carter Humanitarian Award is presented annually by the National Foundation for Infectious Diseases (NFID) to honor individuals whose outstanding humanitarian efforts and achievements have contributed significantly to improving global public health through domestic and/or international activities. Priority is given to contributions in the area of infectious diseases. Selection criteria include: Humanitarian service; Public education contributions; and/or Legislative or policy achievements. Nominations for the 2027 NFID Jimmy and Rosalynn Carter Humanitarian Award will open in 2027.

The Maxwell Finland Award for Scientific Achievement is presented annually by the National Foundation for Infectious Diseases (NFID) to honor scientists who have made outstanding contributions to the understanding of infectious diseases and public health. Selection criteria include: Excellence in clinical and/or research activities; Participation in the training of future leaders in the field; and Positive impact on global public health through domestic and/or international activities. Nominations for the 2027 Maxwell Finland Award for Scientific Achievement will open in 2027.

This notice of funding opportunity (NOFO) invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. This mechanism may also be used to support development of a new resource to the broader scientific community of the National Institute of Allergy and Infectious Diseases (NIAID). It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate.The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.

Conference takes place October 14-16, 2026 in Manipal, India. Registration now open! Organized in partnership by Nature Medicine, Nature Microbiology, Nature Health, Nature Communications, and MAHE, this conference will bring together leading voices in infectious disease research to explore innovative solutions to global health challenges. As the world faces rising threats from emerging pathogens, climate change, and antimicrobial resistance, the event will highlight advances in surveillance, diagnostics, drug development, and vaccination strategies. Program highlights include: Disease surveillance, modelling and forecasting Antimicrobial resistance and drug development Challenges in diagnostic and screening Disease prevention strategies Future of vaccination and disease eradication Climate change and One Health approaches Pandemic preparedness

Background: Conversational chatbots are increasingly integrated into daily life, including in health-related information-seeking, decision support, social interaction, and informal caregiving contexts. These systems are now used by individuals to interpret symptoms, manage chronic conditions, make financial and health decisions, and mitigate social isolation, often without professional oversight. Use of chatbot technologies is expanding rapidly, and patterns of adoption, benefit, and risk are likely to differ across populations, contexts, and system designs. At present, there is insufficient evidence regarding the benefits and harms of chatbot use for health and well-being or to characterize unintended consequences such as misinformation, over-reliance, altered decision-making, or delayed engagement with professional care. Rigorous research is needed to understand how chatbot design (including potential built-in safeguards), chatbot use (including but not limited to context and frequency of use), and user characteristics interact to shape health-relevant outcomes. Efforts should inform safeguards, standards, and evidence-based guidance. Purpose: This topic encourages multidisciplinary research that identifies, measures, and explains the benefits and harms associated with chatbot use (both chatbot-based interventions or treatments and routine chatbot use) across a variety of populations, use cases, and settings. Of interest are studies that move beyond proof-of-concept to characterize mechanisms, safety, and impacts on behavior, decision-making, and health outcomes. Of particular interest are studies that: - Identify risk mechanisms: including automation bias, persuasive effects, misinformation exposure, behavioral dependency, and substitution for professional care, and document adverse outcomes across different chatbot designs, and health or wellbeing-related purposes. - Compare safety and performance across chatbot models, including adaptive versus static designs and varying degrees of personalization, information retrieval, or relational engagement. - Examine impacts on decision-making and autonomy: including how chatbot use influences judgment, independence, help-seeking behavior, and relationships with family, caregivers, and clinicians. - Characterize health and functional outcomes associated with patterns of use: including frequency, duration, and longitudinal engagement, with attention to cognitive, emotional, social, and behavioral consequences. - Develop and test safeguards: including monitoring strategies and design features that promote safe, ethical, secure, and beneficial use, particularly for populations at elevated risk of harm. - Ideally, studies will focus on advancing understanding of causal mechanisms driving observed or hypothesized effects and emphasize methodological rigor, appropriate comparators, and real-world relevance.